1. β-Glucocerebrosidase activity in GBA-linked Parkinson disease
- Author
-
Ann L. Hunt, John H. Growdon, Ganqiang Liu, Bradley T. Hyman, Joseph J. Locascio, Stephen N. Gomperts, Clemens R. Scherzer, Yuliya I. Kuras, Aleksandar Videnovic, Albert Y. Hung, Michael A. Schwarzschild, Anne-Marie Wills, Michael T. Hayes, Idil Tuncali, Todd M. Herrington, Ming Sum Ruby Chiang, Zhixiang Liao, Young Eun Huh, Karbi Choudhury, and Sergio Pablo Sardi
- Subjects
0301 basic medicine ,Mutation ,medicine.medical_specialty ,business.industry ,Cross-sectional study ,Disease ,medicine.disease_cause ,Gastroenterology ,03 medical and health sciences ,Glucocerebrosidase activity ,030104 developmental biology ,0302 clinical medicine ,Interquartile range ,Endophenotype ,Internal medicine ,Severity of illness ,Medicine ,In patient ,Neurology (clinical) ,business ,030217 neurology & neurosurgery - Abstract
ObjectiveTo test the relationship between clinically relevant types of GBA mutations (none, risk variants, mild mutations, severe mutations) and β-glucocerebrosidase activity in patients with Parkinson disease (PD) in cross-sectional and longitudinal case-control studies.MethodsA total of 481 participants from the Harvard Biomarkers Study (HBS) and the NIH Parkinson's Disease Biomarkers Program (PDBP) were analyzed, including 47 patients with PD carrying GBA variants (GBA-PD), 247 without a GBA variant (idiopathic PD), and 187 healthy controls. Longitudinal analysis comprised 195 participants with 548 longitudinal measurements over a median follow-up period of 2.0 years (interquartile range, 1–2 years).Resultsβ-Glucocerebrosidase activity was low in blood of patients with GBA-PD compared to healthy controls and patients with idiopathic PD, respectively, in HBS (p < 0.001) and PDBP (p < 0.05) in multivariate analyses adjusting for age, sex, blood storage time, and batch. Enzyme activity in patients with idiopathic PD was unchanged. Innovative enzymatic quantitative trait locus (xQTL) analysis revealed a negative linear association between residual β-glucocerebrosidase activity and mutation type with p < 0.0001. For each increment in the severity of mutation type, a reduction of mean β-glucocerebrosidase activity by 0.85 μmol/L/h (95% confidence interval, −1.17, −0.54) was predicted. In a first longitudinal analysis, increasing mutation severity types were prospectively associated with steeper declines in β-glucocerebrosidase activity during a median 2 years of follow-up (p = 0.02).ConclusionsResidual activity of the β-glucocerebrosidase enzyme measured in blood inversely correlates with clinical severity types of GBA mutations in PD. β-Glucocerebrosidase activity is a quantitative endophenotype that can be monitored noninvasively and targeted therapeutically.
- Published
- 2020